EASL Studio - Exploring new frontiers: The AI liver taskforce initiative

Faculty

• Eric Trépo (Moderator)
• Tom Lüdde (Faculty)
• Jakob Kather (Faculty)
• Raquel Pérez-López (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Advances in systemic treatments in liver cancer

Faculty

• Josep Llovet (Moderator)
• Massimo Iavarone (Faculty)
• Matthias Pinter (Faculty)
• Jessica Zucman-Rossi (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Buongiorno Milano: What not to miss during EASL Congress.

Faculty

• Aleksander Krag (Moderator)
• Debbie Shawcross (Faculty)
• Thomas Berg (Faculty)
• Ahmed Elsharkawy (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

This session covers a wide range of topics relevant to the current landscape of viral hepatitis, including elimination efforts, resistance to direct-acting antivirals (DAAs), surveillance methods during and after therapy. This talk provides you with valuable insights through an up-to-date overview of the latest developments and challenges in the field.

Faculty

• Thomas Berg (Moderator)
• Jordan Feld (Faculty)
• Norah Terrault (Faculty)
• Heiner Wedemeyer (Faculty)

This episode is scheduled in honour of the United States’ Viral Hepatitis Awareness Month.

This EASL Studio is supported by GSK and Vir Biotechnology. EASL has received no input from GSK or Vir Biotechnology with regards to the content of this programme.

Related episodes

• Season 6, Episode 2: Why do we need HBV functional cure?
• Season 5, Episode 8: JHEP Live: Hepatitis Delta’s Latest Debate: Updates Straight from EASL’s Slate
• Season 5, Episode 3: Zoonotic Hepatitis E: What’s hot in 2023?
• EASL Studio at the EASL Congress 2023: The bumpy road of Hepatitis B drug development successes and challenges
• Season 4, Episode 19: HDV: The devil becomes treatable
• Season 4, Episode 1: Hepatitis B elimination: how far behind are we and what do we need to change to achieve it?

All EASL Studio Podcasts are available on EASL Campus.

This insightful discussion is centred on the burgeoning field of endohepatology, where advanced endoscopic techniques revolutionise hepatology practice. With this episode, explore the broad scope of endoscopic procedures (including EUS-guided liver biopsy, portal pressure measurement, and gastric varices embolisation) and their transformative impact on diagnostics and therapeutic interventions in liver disease.

To learn even more about endoscopic procedures in hepatology, take a look at this study by Wim Laleman et al., published in January 2024 in the Journal of Hepatology.

Faculty 

• Wim Laleman (Moderator)
• Andres Cardenas (Faculty)
• Gavin Johnson (Faculty)
• Reem Sharaiha (Faculty)

Related episodes

• Season 6, Episode 11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?
• Season 3, Episode 15: Chronic portal vein thrombosis: anticoagulation and interventional radiology for all patients?
• Season 2, Episode 14: Elastography – The new non-invasive gold standard in portal hypertension?

All EASL Studio Podcasts are available on EASL Campus.

This episode explores the approval of resmetirom for NASH, analysing its integration into clinical practice and patient eligibility. The experts also discuss the role of lifestyle interventions alongside resmetirom, the use of biomarkers for patient selection, treatment monitoring, and the expected landscape changes over the next five years.

Faculty

• Aleksander Krag (Moderator)
• Naim Alkhouri (Faculty)
• Sven Francque (Faculty)
• Amalia Gastaldelli (Faculty)

Related episodes

• Season 5 , Episode 2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathways
• EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
• Season 4, Episode 23: The Conundrum of NASH: The Growing Global Disease Burden with Low Disease Awareness
• Season 4, Episode 22: JHEP Live: New and promising drugs for NASH on the horizon

All EASL Studio Podcasts are available on EASL Campus.

Join us for a critical discussion on the significance of Drug and Herbal & Dietary Supplement-Induced Liver Injury (DHILI). In this episode, the speakers explore the importance of DHILI, assess recent advancements, and deliberate on the obstacles hindering further progress in addressing this pressing healthcare concern.

This episode is organised in collaboration with the EASL DHILI Consortium.

Faculty

• Guruprasad Padur Aithal (Moderator)
• Paul Hayashi (Faculty)
• Maribel Lucena (Faculty)
• Paul Watkins (Faculty)

Related episodes

• Season 4, Episode 20 – COST Actions: opportunities for pan-European collaborations in liver diseases

All EASL Studio Podcasts are available on EASL Campus.

In this episode, experts explore the shift away from invasive measurements in assessing clinically significant portal hypertension. The speakers address the crucial data needed to enhance the reliability and applicability of these non-invasive methods and introduce several advanced elastography techniques, shaping the future of portal hypertension assessment.

Faculty

• Bogdan Procopet (Moderator)
• Maria Papp (Faculty)
• Atoosa Rabiee (Faculty)
• Thomas Reiberger (Faculty)

Related episode

• EASL Studio S2E14: Elastography – The new non-invasive gold standard in portal hypertension?

All EASL Studio Podcasts are available on EASL Campus.

This episode aims at highlighting the importance of patient and public involvement in research. More precisely, the speakers focus on the importance of involving patients in research, practical steps to involve patients in research, and insights from EASL including engagement of patients in the EASL-Lancet Commission.

Faculty

• Marta Alonso-Peña (Moderator)
• Kate Jack (Faculty)
• Marko Korenjak (Faculty)
• Thomas Marjot (Faculty)

Related episode

• EASL Studio from EASL Congress 2023: United we stand: Global societies collaborating to beat liver disease.

All EASL Studio Podcasts are available on EASL Campus.

This episode centres around an article recently published in the Journal of Hepatology, presenting a new treatment algorithm positioned as an evolution of the BCLC system and aimed at addressing its limitations in the staging and therapy hierarchy for HCC. This discussion covers the implications of this fresh approach in the management of HCC patients, challenging the standard paradigm.

Faculty

• Bruno Sangro (Moderator)
• Umberto Cillo (Faculty) 
• Helen Reeves (Faculty)
• María Reig (Faculty)

This EASL Studio is supported by AstraZeneca. EASL has received no input from AstraZeneca with regards to the content of this programme.

Related episodes

• EASL Studio S5E13: Basics in decision-making for liver cancer treatment
• EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
• EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
• EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
• EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
• EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?
• EASL Studio S2E15: JHEP Live on the best animal model for HCC – Lost in translation?

All EASL Studio Podcasts are available on EASL Campus.